100 Nagog Park
Acton, MA 01720
United States
978 600 7000
https://www.insulet.com
Sector(es): Healthcare
Industria: Medical Devices
Empleados a tiempo completo: 3,000
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Dr. James R. Hollingshead Ph.D. | President, CEO & Director | 2.88M | N/D | 1963 |
Ms. Laetitia Cousin | Senior VP of Regulatory Affairs, Quality Assurance & Compliance | N/D | N/D | 1976 |
Angela Geryak Wiczek | Senior Director of Corporate Communications | N/D | N/D | N/D |
Mr. Philip Hildale | Senior Vice President of Sales & Customer Care | N/D | N/D | N/D |
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
La calificación ISS Governance QuickScore de Insulet Corporation a partir del 1 de abril de 2024 es 9. Las puntuaciones principales son Auditoría: 6; Junta: 7; Derechos del accionista: 10; Compensación: 8.